{
    "clinical_study": {
        "@rank": "9982", 
        "arm_group": {
            "arm_group_label": "RO5424802", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This non-randomized, single group, open-label study will investigate the mass balance,\n      routes of elimination, pharmacokinetics, and metabolism of a single oral dose of RO5424802\n      and the pharmacokinetics of a 14C-labeled tracer in healthy volunteers"
        }, 
        "brief_title": "A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male adults, 18 to 45 years of age, inclusive\n\n          -  Body mass index (BMI) from 18 to 32 kg/m2, inclusive\n\n          -  Willingness to use effective contraception as outlined in the protocol\n\n          -  Willingness to abstain from alcohol and xanthine-containing beverages or food\n             (coffee, tea, cola, chocolate and \"energy drinks\") from 72 hours prior to the first\n             dose until discharged\n\n          -  Willingness to avoid prolonged sun exposure and guard against sunburn during study &\n             follow-up\n\n        Exclusion Criteria:\n\n          -  Clinically significant medical history or findings in physical examination, vital\n             signs, or laboratory test results prior to study start\n\n          -  Positive screening tests for hepatitis B or C, HIV, alcohol, drugs of abuse, or\n             tobacco\n\n          -  Regular smoking within 6 months prior to first dosing. Subjects should avoid smoky\n             environments for at least 1 week prior to each cotinine screen\n\n          -  Excessive alcohol consumption\n\n          -  Use of any metabolic inducers (including herbals such as St. John's Wort) within 4\n             weeks or 5 half-lives (whichever is longer) before the first dose of study\n             medication, including but not limited to: rifampin, rifabutin, glucocorticoids,\n             carbamazepine, phenytoin and phenobarbital\n\n          -  Regular work with ionizing radiation or radioactive material\n\n          -  Subjects enrolled in a previous radiolabel study or who have received radiotherapy\n             within 12 months prior to first dosing such that total radioactivity over a 12 month\n             period would exceed an acceptable radiation burden > 0.1 mSv\n\n          -  Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays\n             of thorax and bony skeleton [excluding spinal column]), during work or participation\n             in a medical trial in the previous year\n\n          -  Strenuous activity, sunbathing, or contact sports are not allowed from 4 days prior\n             to entry into the clinical site until study follow-up\n\n          -  Participation in an investigational drug or device study within 60 days (or 6 months\n             for biologic therapies) prior to first dosing"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981005", 
            "org_study_id": "NP28989"
        }, 
        "intervention": {
            "arm_group_label": "RO5424802", 
            "description": "Single oral doses followed by IV or oral administration of a 14C-labeled tracer", 
            "intervention_name": "RO5424802", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands", 
                    "zip": "9471 GP"
                }
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE 1, SINGLE-CENTER, OPEN-LABEL STUDY INVESTIGATING THE EXCRETION BALANCE, PHARMACOKINETICS AND METABOLISM OF A SINGLE ORAL DOSE AND PHARMACOKINETICS OF AN INTRAVENOUS TRACER OF [14-C]-RO5424802 IN HEALTHY MALE SUBJECTS", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Elimination: Amount of drug excreted in urine/feces over the study period", 
                "safety_issue": "No", 
                "time_frame": "Days 11 to 15"
            }, 
            {
                "measure": "Pharmacokinetics: Bioavailability (Area under the plasma concentration-time curve [AUC]) after administration of RO5424802", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 25"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981005"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 25"
            }, 
            {
                "measure": "Pharmacokinetics: Metabolite identification in plasma, urine, and feces.", 
                "safety_issue": "No", 
                "time_frame": "Days 11 to 25"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}